Lv5
910 积分 2024-09-29 加入
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
9天前
已完结
USP21 accelerates the proliferation and glycolysis of esophageal cancer cells by regulating the STAT3/FOXO1 pathway
2个月前
已完结
Inhibition of USP21 leads to ovarian carcinoma cell death by suppressing MAPK signaling
2个月前
已完结
On the relationship between hERG inhibition and the magnitude of QTc prolongation: An in vitro to clinical translational analysis
2个月前
已完结
Oncolytic virus preclinical toxicology studies
2个月前
已完结
Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology
2个月前
已完结
In vivo integrated safety assessment of the cardiovascular system in drug development
2个月前
已关闭
Safety pharmacology 2023 and implementation of the ICH E14/S7B Q&A guidance document
2个月前
已完结
Oncolytic virus preclinical toxicology studies
3个月前
已完结
Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2022 and 2023
4个月前
已完结
皖公网安备34019202002308
